Switch theme
Sign up to access all valuation multiples
Jamjoom Pharmaceuticals Factory Co is engaged in the development, manufacture, and marketing of a wide range of high-quality branded generic pharmaceuticals, including pharmaceuticals and consumer health products, with the majority of revenue coming from pharmaceutical sales. Geographically the company has a presence in the Kingdom of Saudi Arabia, the Gulf, Iraq, Egypt, North Africa, and other export markets.
1994
1.1K+
LTM Revenue $381M
LTM EBITDA $129M
$3.2B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Jamjoom Pharma has a last 12-month revenue (LTM) of $381M and a last 12-month EBITDA of $129M.
In the most recent fiscal year, Jamjoom Pharma achieved revenue of $352M and an EBITDA of $112M.
Jamjoom Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Jamjoom Pharma valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $381M | XXX | $352M | XXX | XXX | XXX |
| Gross Profit | $236M | XXX | $219M | XXX | XXX | XXX |
| Gross Margin | 62% | XXX | 62% | XXX | XXX | XXX |
| EBITDA | $129M | XXX | $112M | XXX | XXX | XXX |
| EBITDA Margin | 34% | XXX | 32% | XXX | XXX | XXX |
| EBIT | $114M | XXX | $108M | XXX | XXX | XXX |
| EBIT Margin | 30% | XXX | 31% | XXX | XXX | XXX |
| Net Profit | $110M | XXX | $95.2M | XXX | XXX | XXX |
| Net Margin | 29% | XXX | 27% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 16, 2025, Jamjoom Pharma's stock price is SAR 176 (or $47).
Jamjoom Pharma has current market cap of SAR 12.3B (or $3.3B), and EV of SAR 12.1B (or $3.2B).
See Jamjoom Pharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3.2B | $3.3B | XXX | XXX | XXX | XXX | $1.57 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 16, 2025, Jamjoom Pharma has market cap of $3.3B and EV of $3.2B.
Jamjoom Pharma's trades at 9.2x EV/Revenue multiple, and 28.9x EV/EBITDA.
Equity research analysts estimate Jamjoom Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Jamjoom Pharma has a P/E ratio of 29.7x.
See valuation multiples for Jamjoom Pharma and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $3.3B | XXX | $3.3B | XXX | XXX | XXX |
| EV (current) | $3.2B | XXX | $3.2B | XXX | XXX | XXX |
| EV/Revenue | 8.5x | XXX | 9.2x | XXX | XXX | XXX |
| EV/EBITDA | 25.2x | XXX | 28.9x | XXX | XXX | XXX |
| EV/EBIT | 28.4x | XXX | 30.0x | XXX | XXX | XXX |
| EV/Gross Profit | 13.7x | XXX | n/a | XXX | XXX | XXX |
| P/E | 29.7x | XXX | 34.5x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 58.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialJamjoom Pharma's last 12 month revenue growth is 14%
Jamjoom Pharma's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.1M for the same period.
Jamjoom Pharma's rule of 40 is 45% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Jamjoom Pharma's rule of X is 70% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Jamjoom Pharma and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 14% | XXX | 14% | XXX | XXX | XXX |
| EBITDA Margin | 34% | XXX | 32% | XXX | XXX | XXX |
| EBITDA Growth | 13% | XXX | 23% | XXX | XXX | XXX |
| Rule of 40 | 45% | XXX | 46% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 70% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 14% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 3% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 31% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Jamjoom Pharma acquired XXX companies to date.
Last acquisition by Jamjoom Pharma was XXXXXXXX, XXXXX XXXXX XXXXXX . Jamjoom Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Jamjoom Pharma founded? | Jamjoom Pharma was founded in 1994. |
| Where is Jamjoom Pharma headquartered? | Jamjoom Pharma is headquartered in Saudi Arabia. |
| How many employees does Jamjoom Pharma have? | As of today, Jamjoom Pharma has 1.1K+ employees. |
| Is Jamjoom Pharma publicy listed? | Yes, Jamjoom Pharma is a public company listed on SAU. |
| What is the stock symbol of Jamjoom Pharma? | Jamjoom Pharma trades under 4015 ticker. |
| When did Jamjoom Pharma go public? | Jamjoom Pharma went public in 2023. |
| Who are competitors of Jamjoom Pharma? | Similar companies to Jamjoom Pharma include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Jamjoom Pharma? | Jamjoom Pharma's current market cap is $3.3B |
| What is the current revenue of Jamjoom Pharma? | Jamjoom Pharma's last 12 months revenue is $381M. |
| What is the current revenue growth of Jamjoom Pharma? | Jamjoom Pharma revenue growth (NTM/LTM) is 14%. |
| What is the current EV/Revenue multiple of Jamjoom Pharma? | Current revenue multiple of Jamjoom Pharma is 8.5x. |
| Is Jamjoom Pharma profitable? | Yes, Jamjoom Pharma is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Jamjoom Pharma? | Jamjoom Pharma's last 12 months EBITDA is $129M. |
| What is Jamjoom Pharma's EBITDA margin? | Jamjoom Pharma's last 12 months EBITDA margin is 34%. |
| What is the current EV/EBITDA multiple of Jamjoom Pharma? | Current EBITDA multiple of Jamjoom Pharma is 25.2x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
